Matriks Biotek专门生产针对抗体药的ELISA试剂盒，用于检测抗体药的体内含量或因用于产生的针对相应抗体药的抗体的体内含量。Matriks Biotek®, SHIKARI®和KLONART®为Matriks生物技术公司注册的产品商标。其产品达到ISO 13485 & CE IVD标准。
MatriksBiotek2020年价格表
| 货号 | 品名 | cas | 价格j |
| INF-FD-REMI | Shikari® Infliximab | Shikari® (Q-INFLIXI) | 14500 |
| INF-QLS-REMI | Shikari® Qualitative Antibodies to Infliximab | Shikari® (Q-ATI) | 14500 |
| INF-QNS-REMI | Shikari® Quantitative Antibodies to Infliximab | Shikari® (Q-ATI) | 15000 |
| INF-QNFT-REMI | Shikari® Semi-Quantitative Antibodies (Free/Total) to Infliximab | Shikari® (Q-ATIDUO) | 15000 |
| INF-FD-REMS | Shikari® Infliximab | Shikari® (Q-REMS) | 14500 |
| INF-QLS-REMS | Shikari® Qualitative Antibodies to Infliximab | Shikari® (S-AIR) | 14500 |
| INF-QNS-REMS | Shikari® Quantitative Antibodies to Infliximab | Shikari® (S-AIR) | 15000 |
| INF-QNT-REMS | Shikari® Semi-Quantitative Antibodies (Free/Total) to Infliximab | Shikari® (S-AIR) | 15000 |
| ADA-FD-HUM | Shikari® Adalimumab | Shikari® (Q-ADA) | 14500 |
| ADA-QLS-HUM | Shikari® Qualitative Antibodies to Adalimumab | Shikari® (S-ATA) | 14500 |
| ADA-QNS-HUM | Shikari® Quantitative Antibodies to Adalimumab | Shikari® (S-ATA) | 15000 |
| ADA-QNFT-HUM | Shikari® Semi-Quantitative Antibodies (Free/Total) to Adalimumab | Shikari® (S-ATA) | 15000 |
| ETA-FD-ENB | Shikari® Etanercept | Shikari® (Q-ETA) | 15000 |
| ETA-QLS-ENB | Shikari® Qualitative Antibodies to Etanercept | Shikari® (S-ATE) | 15000 |
| GOL-FD-SIM | Shikari® Golimumab | Shikari® (Q-GOL) | 14500 |
| GOL-QLS-SIM | Shikari® Qualitative Antibodies to Golimumab | Shikari® (S-ATG) | 14500 |
| CER-FD-CIM | Shikari® Certolizumab | Shikari® (Q-CERT) | 15000 |
| VED-FD-ENT | Shikari® Vedolizumab | Shikari® (Q-VEDO) | 16000 |
| VED-QLS-ENT | Shikari® Qualitative Antibodies to Vedolizumab | Shikari® (S-ATV) | 16000 |
| UST-FD-STE | Shikari® Ustekinumab | Shikari® (Q-UST) | 16000 |
| UST-QLS-STE | Shikari® Qualitative Antibodies to Ustekinumab | Shikari® (S-ATU) | 16000 |
| RAM-FD-CYR | Shikari® Ramucirumab | Shikari® (Q-RAM) | 16000 |
| RAM-QLS-CYR | Shikari® Qualitative Antibodies to Ramucirumab | Shikari® (S-ATRAM) | 15000 |
| BEV-FD-AA | Shikari® Bevacizumab | Shikari® (Q-BEVA) | 14500 |
| BEV-QLS-AA | Shikari® Qualitative Antibodies to Bevacizumab | Shikari® (S-ATB) | 14500 |
| BEV-QNS-AA | Shikari® Quantitative Antibodies to Bevacizumab | Shikari® (S-ATB) | 15000 |
| RIT-FD-RM | Shikari® Rituximab | Shikari® (Q-RITUX) | 14500 |
| RIT-QLS-RM | Shikari® Qualitative Antibodies to Rituximab | Shikari® (S-ATR) | 14500 |
| RIT-QNS-RM | Shikari® Quantitative Antibodies to Rituximab | Shikari® (S-ATR) | 15000 |
| TRA-FD-HH | Shikari® Trastuzumab | Shikari® (Q-TRAS) | 14500 |
| TRA-QLS-HH | Shikari® Qualitative Antibodies to Trastuzumab | Shikari® (S-ATT) | 14500 |
| TRA-QNS-HH | Shikari® Quantitative Antibodies to Trastuzumab | Shikari® (S-ATT) | 15000 |
| CET-FD-ERB | Shikari® Cetuximab | Shikari® (Q-CET) | 14500 |
| CET-QLS-ERB | Shikari® Qualitative Antibodies to Cetuximab | Shikari® (S-ATC) | 14500 |
| CET-QNS-ERB | Shikari® Quantitative Antibodies to Cetuximab | Shikari® (S-ATC) | 15000 |
| DEN-FD-PRO | Shikari® Denosumab | Shikari® (Q-DEN) | 16000 |
| DEN-QLS-PRO | Shikari® Qualitative Antibodies to Denosumab | Shikari® (S-ATD) | 16000 |
| FIL-QLS-FRA | Shikari® Qualitative Antibodies to Filgrastim | Shikari® (S-AFA) | 17000 |
| FIL-QNS-FRA | Shikari® Quantitative Antibodies to Filgrastim | Shikari® (Q-AFA) | 19000 |
| OMA-FD-XOL | Shikari® Omalizumab | Shikari® (Q-OMA) | 14500 |
| OMA-QLS-XOL | Shikari® Qualitative Antibodies to Omalizumab | Shikari® (S-ATO) | 14500 |
| RAN-FD-LUC | Shikari® Ranibizumab | Shikari® (Q-RAN) | 16000 |
| AVE-FD-BAV | Shikari® Avelumab | Shikari® (Q-AVE) | 16000 |
| AVE-QLS-BAV | Shikari® Qualitative Antibodies to Avelumab | Shikari® (S-ATAV) | 15000 |
| NIV-FD-OPD | Shikari® Nivolumab | Shikari® (Q-NIVO) | 16000 |
| NIV-QLS-OPD | Shikari® Qualitative Antibodies to Nivolumab | Shikari® (S-ATN) | 15000 |
| PEM-FD-KEY | Shikari® Pembrolizumab | Shikari® (Q-PEM) | 16000 |
| PEM-QLS-KEY | Shikari® Qualitative Antibodies to Pembrolizumab | Shikari® (S-ATP) | 15000 |
| IPI-FD-YER | Shikari® Ipilimumab | Shikari® (Q-IPI) | 16000 |
| IPI-QLS-YER | Shikari® Qualitative Antibodies to Ipilimumab | Shikari® (S-ATI) | 15000 |